Hikma Pharmaceuticals (OTCMKTS:HKMPF) Shares Gap Down – Should You Sell?

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF)’s stock price gapped down before the market opened on Monday . The stock had previously closed at $21.6950, but opened at $20.37. Hikma Pharmaceuticals shares last traded at $20.37, with a volume of 450 shares changing hands.

Analyst Ratings Changes

Separately, Citigroup began coverage on Hikma Pharmaceuticals in a research note on Thursday, July 16th. They issued a “buy” rating on the stock. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Hikma Pharmaceuticals has a consensus rating of “Hold”.

Hikma Pharmaceuticals Price Performance

The company has a current ratio of 1.82, a quick ratio of 1.06 and a debt-to-equity ratio of 0.57. The company has a fifty day simple moving average of $19.81 and a 200-day simple moving average of $19.42.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures and markets a broad range of branded and non-branded generics, specialty injectables and consumer healthcare products. The company’s three core business segments include generic medicines, injectable products and branded generics, serving hospitals, wholesalers and pharmacies worldwide. Its product portfolio spans diverse therapeutic areas such as cardiovascular, oncology, respiratory, pain management and anti-infectives, with an emphasis on injectable solutions for complex hospital treatments.

Founded in 1978 in Amman, Jordan, Hikma has grown through organic expansion and strategic acquisitions to become one of the leading pharmaceutical players in the Middle East, North Africa, Europe and the United States.